Abstract:
Kaempferia parviflora and Myristica fragrans present wide spectrum of neuropharmacological activities and neuroprotective effect in vivo and in vitro, that potentially can be useful in the treatment of neurodegenerative disorder. In recent studies we aims to determine the effects of feeding Kaempferia parviflora ethanolic extract and Myristica fragrans volatile oil on proteomic profiles protein changes developing and the level of monoamine neurotransmitter (norepinephrine, dopamine and serotonin) in hippocampus of sprague dawley rats. The effects of plants on protein changes developing by Two-Dimensional Gel Electrophoresis (2D-gel) protein identified by Liquid chromatography-mass spectrometry (LC-MS/MS). The interest of protein expressions were confirmed by Western blot analysis. The level of monoamine was confirmed by Reverse Phase High Performance Liquid Chromatography (HPLC). The results showed that K. parviflora, M. fragrans and fluoxetine are increasing serotonin (5-HT) norepinephrine and dopamine in rat hippocampus when compared with control. The data from proteomic analysis showed that 37 proteins in K. parviflora group were up-regulated while 14 were down-regulated in. M. fragrans group demonstrated that 27 proteins were up-regulated while 16 were down-regulated. In fluoxetine treatment group we found that 29 proteins were up-regulated and 14 were down-regulated. The level of GFAP, PDIA3, DPYSL2 and p-DPYSL2 were up and down-regulated in hippocampus of K. parviflora, M. fragrans and fluoxetine treated SD rat. In conclusion, K. parviflora, M. fragrans can target and regulate multiple pathways which help to understand the molecular therapeutic underlying mechanism pathway, especially in the level of GFAP, PDIA3, DPYSL2 and p-DPYSL2.
